(Q39351619)

11 September 2017

title

Once-daily evening administration of mometasone furoate in asthma treatment initiation (English)

1 reference

11 September 2017

0 references

George W Bensch

1

1 reference

11 September 2017

Bruce Prenner

2

1 reference

11 September 2017

Robert Berkowitz

3

1 reference

11 September 2017

Stanley Galant

4

1 reference

11 September 2017

Joe Ramsdell

5

1 reference

11 September 2017

Barry Lutsky

6

1 reference

11 September 2017

publication date

1 April 2006

1 reference

Annals of Allergy, Asthma & Immunology

11 September 2017

published in

1 reference

11 September 2017

volume

96

1 reference

11 September 2017

issue

4

1 reference

11 September 2017

page(s)

533-540

1 reference

Inhaled and nasal corticosteroids: safety aspects

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Overcoming barriers to nonadherence in asthma treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

1 reference

7 January 2021

Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Chronobiology of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Elevated serum melatonin is associated with the nocturnal worsening of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Chronobiology and asthma. III. Timing corticotherapy to biological rhythms to optimize treatment goals

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Efficacy of once- and twice-daily administration of budesonide via Turbuhaler as initial therapy in patients with mild persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Systemic bioavailability of inhaled corticosteroids: appropriate and comparable methodology.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

Drug delivery performance of the mometasone furoate dry powder inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

An easy-to-use dry-powder inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963547-8

7 January 2021

10.1016/S1081-1206(10)63547-8

Identifiers

DOI

1 reference

11 September 2017

1 reference